Currently, the most widely used immunotherapies for cancer patients are checkpoint inhibitors, specifically monoclonal antibodies against PD-1/PD-L1 and CTLA-4, that work by blocking one of the pathways that contribute to CD8+ T cell exhaustion [199]. Here, CD8A is linked to cancer.